Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 7Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 4Breast Neoplasms 2Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Plasma Cell 1Neoplasms 1Melanoma 1Glioma 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Brain Neoplasms 1Bone Neoplasms 1

Interventions

pembrolizumab 26Cyclophosphamide 20Nivolumab 14Doxorubicin 13Surveys and Questionnaires 9Exercise 9Carboplatin 9atezolizumab 8Vincristine 8Rituximab 8Radiotherapy 8Prednisone 8Paclitaxel 8Dexamethasone 8Bevacizumab 8venetoclax 7fludarabine 7Fluorouracil 7Docetaxel 7Blood Specimen Collection 7lenvatinib 6dostarlimab 6cemiplimab 6budigalimab 6Pemetrexed 6Oxaliplatin 6Cisplatin 6durvalumab 5Leucovorin 5Lenalidomide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasms × poly ICLC × Clear all
NCT03223103 2025-09-10

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

Albert Einstein College of Medicine

Phase 1 Active not recruiting
13 enrolled
CNS

Brain Neoplasms, Glioblastoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡